| Value | ₹3.00 Cr |
|---|
NSE filing, NSE: WABAG. Summary written from the filing by ALFA Finder's alert engine.
Va Tech Wabag Ltd: key numbers
- Share price
- ₹1,812.30
- Market cap
- ₹11,330 Cr
- Revenue (annual)
- ₹3,944 Cr
- Net profit (annual)
- ₹370.5 Cr
- P/E (TTM)
- 28.7×Sector 21.3×
- Promoter holding
- 19.03%-0.05% QoQ
- FII holding
- 18.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Va Tech Wabag Ltd
All →Va Tech Wabag Board Meeting Date
VA Tech Wabag Ltd scheduled its next Board Meeting for 5 November 2026 to approve Q2/H1 FY27 results. The trading window stays closed until 48 hours after results declaration.
Va Tech Wabag Bags ₹1,000 Cr Order from Reliance Industries Limited
WABAG secured a 'Mega' order from Reliance Industries for a desalination and remineralisation plant at Jamnagar. The order is executed in phases over 25 months, but no rupee value is disclosed.
- Value
- ₹1,000 Cr
- From
- Reliance Industries Limited (RIL)
- Execution
- In phases over 25 months
- desalination plant capacity
- 8400.0 m3/hr
Va Tech Wabag Other Announcement
VA Tech Wabag Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026, as mandated by SEBI regulations.
Va Tech Wabag Employee Stock Options
VA TECH WABAG LIMITED has allotted equity shares under its ESOP/ESPS scheme. This corporate action updates the company's total paid-up share capital.
Va Tech Wabag Employee Stock Options
VA Tech Wabag allotted 23,261 equity shares under the Centenary Stock Option Scheme 2023. The exercise price for these shares is Rs. 1.19 Crore.
- Value
- ₹1.19 Cr
Va Tech Wabag Bags ₹100 Cr Order from Reliance Industries Limited
VA Tech Wabag secured a medium-sized order from Reliance Industries for an effluent treatment plant at Jamnagar. The project will be executed over 13 months.
- Value
- ₹100.0 Cr
- From
- Reliance Industries Limited (RIL)
- Execution
- 13 months
Other acquisition announcements
All →Kalpataru Acquisition Worth ₹52.55 Cr
Kalpataru's subsidiary KPL approved acquiring 16.67% of step-down subsidiaries AREPL and AREDPL for ₹52.55 Crore. This makes them wholly owned, giving Kalpataru 100% of Kalpataru Parkcity project cash flows at Thane.
- Value
- ₹52.55 Cr
- Execution
- 60 days, subject to receipt of requisite approvals
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Arvaya Healthcare Acquisition
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Affle 3I Acquisition Worth ₹3,990 Cr
Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.
- Value
- ₹3,990 Cr
- Execution
- Expected to close in early 2027